Featured Story | By Nick Paul Taylor Takeda’s Wave 1 pipeline is threatening to peter out into a ripple. The latest setback comes from a phase 3 blood cancer clinical trial, which found adding pevonedistat to chemotherapy did nothing to improve event-free survival. read more |
| |
|---|
|
|  | QIAGEN’s Biotech Grants 2021 - Open Now QIAGEN is offering young biotech companies in North America and Europe the chance to win grants worth up to $100,000 in products and instruments per region. Check your eligibility and apply by September 17, 2021. Apply Now. |
Top Stories By Nick Paul Taylor Investors are taking the departure of Avidity Biosciences’ chief medical officer badly. After learning Jae Kim had left for personal reasons, just days after giving his notice and on the day Avidity posted details of its first study to ClinicalTrials.gov, investors drove the stock down 19%. read more By Ben Adams Assembly Biosciences saw its shares dragged down more than 20% Wednesday evening after it was forced to toss out a midstage hepatitis B treatment due to safety concerns. read more Sponsored by: Almac Group When your goal is to identify effective and ineffective treatments more quickly than traditional trials through a Complex Innovative Design, the right IRT system is crucial. read more By Annalee Armstrong Evotec is headed to the bank with a cool $20 million after Bristol Myers Squibb opted in on a neurodegenerative medicine called EVT8683. The licensing opt-in could also trigger $250 million in milestone payments down the line plus royalties on future sales. read more By Ben Adams Disc Medicine has raised $90 million in a series B round as it looks to push on with its pipeline of early- to midstage blood disorder assets. read more By Conor Hale The deal will see Baxter purchase all of Hill-Rom’s outstanding stock at a price of $156 per share, up from the previous reported offer of $144 apiece and a step above the $150 figure reported earlier this week. read more By Angus Liu AbbVie’s megablockbuster Rinvoq ambition suffers a blow thanks to an updated safety warning and treatment restriction from the FDA. But pharma watchers have different opinions on just how significant the impact may be. read more By Noah Higgins-Dunn There's "room for surprises" when it comes to the safety of Biogen's Aduhelm because of the company's tightly controlled clinical trials, which recruited a narrower group of Alzheimer's patients compared to the treatment's FDA label, RBC Capital Markets wrote on Wednesday, citing a recent study. read more By Dave Muoio Carbon Health's expanding clinic footprint, Verily's first-ever purchase and more merger and acquisition news from the month of August. read more Resources Sponsored by: Patheon by Thermo Fisher Scientific Choose the right AAV platform for your viral vector-based therapy Sponsored by: XIFIN inc. Download the Value of Precision Medicine Informatics (PMI) Initiatives report to learn about the technology, data types, and the value derived from more than 100 PMI initiatives. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: EVERSANA Today’s economics do not allow manufactures to keep making decisions in an antiquated way. They need to challenge tradition & deliver faster, cheaper, successful launches. Learn how. Sponsored by: Thermo Fisher Scientific Thermo Fisher Scientific introduces a new NK cell culture medium designed to support feeder-free, high-yield growth for cell therapy applications. Sponsored by: Blue Matter This white paper provides a concise overview of the trends currently shaping the market access environment in Europe, as well as the implications for biopharma companies. Sponsored by: Cascade Chemistry by Aceto Read four customer success stories and four success factors that helped move pharmaceutical customers of Cascade Chemistry by Aceto quickly and effectively to clinic with trial-ready APIs. Sponsored by: ConnectiveRx Topple barriers to getting patients started on therapy. Guide them with mobile. Sponsored By: LabVantage Solutions, Inc. Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
